Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Case based Learning: Whole genome sequencing in Prostate Cancer
Câncer de próstata Published 2 anos ago
ASCO Genitourinary Cancers Symposium– Your Top Takeways for Prostate Cancer
Câncer de próstata Published 2 anos ago
Practical Guide for Clinicians on Genomic Testing in Patients with Metastatic Castration Resistant Prostate Cancer
Câncer de próstata Published 2 anos ago
Content
Câncer de próstata
7m 6s
Treating Metastatic Hormone Refractory Prostate Cancer - My Approach
Publicados11 Jul 2022
Revised definition of Castration Resistant Prostate Cancer (mCRPC) considers castration range testosterone with either biochemical progression with three consecutive rises in PSA or evidence of radiological progression. There are three paradigms of treatment of prostate Cancer : Progression post ADT , Progression post upfront Docetaxel , Progression post upfront Androgen Receptor Targeted Agents (ARTA). Switching from one treatment to another is recommended if any two of the three criterions are met: PSA progression , radiological progression , symptomatic progression.
